MX2016010993A - Plasmidos inmunoestimuladores. - Google Patents
Plasmidos inmunoestimuladores.Info
- Publication number
- MX2016010993A MX2016010993A MX2016010993A MX2016010993A MX2016010993A MX 2016010993 A MX2016010993 A MX 2016010993A MX 2016010993 A MX2016010993 A MX 2016010993A MX 2016010993 A MX2016010993 A MX 2016010993A MX 2016010993 A MX2016010993 A MX 2016010993A
- Authority
- MX
- Mexico
- Prior art keywords
- immunostimulatory
- methods
- antibiotic resistance
- dna sequence
- immunostimulatory plasmids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16771—Demonstrated in vivo effect
Abstract
La presente invención se refiere a composiciones inmunomoduladoras y métodos de uso, así como métodos de fabricación. Las composiciones inmunomoduladoras comprenden plásmidos inmunoestimuladores, o una secuencia de ADN, capaces de provocar una respuesta inmune en un sujeto receptor. Además, los plásmidos inmunoestimuladores, o secuencia de ADN, no contienen una secuencia de resistencia a los antibióticos secuencia de codificación para ayudar a reducir el potencial de transferencia horizontal de resistencia a los antibióticos en una población.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461946372P | 2014-02-28 | 2014-02-28 | |
PCT/EP2015/054131 WO2015128461A1 (en) | 2014-02-28 | 2015-02-27 | Immunostimulatory plasmids |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016010993A true MX2016010993A (es) | 2017-05-01 |
Family
ID=52598746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010993A MX2016010993A (es) | 2014-02-28 | 2015-02-27 | Plasmidos inmunoestimuladores. |
Country Status (20)
Country | Link |
---|---|
US (2) | US10155950B2 (es) |
EP (1) | EP3110940A1 (es) |
JP (1) | JP6772065B2 (es) |
KR (1) | KR20160122849A (es) |
CN (1) | CN106029867B (es) |
AU (1) | AU2015222102B2 (es) |
BR (1) | BR112016019837A2 (es) |
CA (1) | CA2940794C (es) |
CL (1) | CL2016002146A1 (es) |
CR (1) | CR20160393A (es) |
DO (1) | DOP2016000223A (es) |
IL (1) | IL247065A0 (es) |
MX (1) | MX2016010993A (es) |
PE (1) | PE20170404A1 (es) |
PH (1) | PH12016501705A1 (es) |
RU (1) | RU2740492C2 (es) |
SV (1) | SV2016005263A (es) |
UA (1) | UA118374C2 (es) |
WO (1) | WO2015128461A1 (es) |
ZA (1) | ZA201605495B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6772065B2 (ja) * | 2014-02-28 | 2020-10-21 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | 免疫賦活プラスミド |
TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CR20180003A (es) * | 2015-06-26 | 2018-03-20 | Bayer Animal Health Gmbh | Métodos de modulación de moléculas de vigilancia de adn citosólicas |
CN108712912B (zh) * | 2015-07-31 | 2022-05-10 | 拜耳动物保健有限责任公司 | 在水生物种中增强的免疫应答 |
SG10202000891UA (en) * | 2015-07-31 | 2020-03-30 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
JP2019525935A (ja) * | 2016-07-26 | 2019-09-12 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | ウシ種の繁殖力の増加 |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
BR112020011815A2 (pt) * | 2017-12-15 | 2020-11-17 | Bayer Animal Health Gmbh | oligonucleotídeos imunoestimulatórios |
CN109646435B (zh) * | 2019-01-11 | 2021-08-03 | 山东省农业科学院奶牛研究中心 | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
ES2308069T3 (es) | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
US20040002472A1 (en) | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
US6517218B2 (en) | 2000-03-31 | 2003-02-11 | Relume Corporation | LED integrated heat sink |
HUP0303924A2 (hu) * | 2001-04-24 | 2004-03-01 | Innogenetics N.V. | Core-glikozilált HCV-burokproteinek |
CA2452666A1 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
AU2002953015A0 (en) * | 2002-12-02 | 2002-12-12 | Women's And Children's Hospital | Modified lacz gene |
WO2004093906A1 (en) | 2003-03-26 | 2004-11-04 | Wyeth | Immunogenic composition and methods |
JP2007509040A (ja) | 2003-10-11 | 2007-04-12 | イネックス ファーマシューティカルズ コーポレイション | 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物 |
US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
JP2008511545A (ja) * | 2004-08-13 | 2008-04-17 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | 抗生物質耐性欠失dnaワクチン |
UY29915A1 (es) | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
TWM297441U (en) | 2006-03-30 | 2006-09-11 | Cheng-Jiun Jian | LED projection light source module |
US7663229B2 (en) | 2006-07-12 | 2010-02-16 | Hong Kong Applied Science And Technology Research Institute Co., Ltd. | Lighting device |
ES2605020T3 (es) * | 2006-10-06 | 2017-03-10 | The Scripps Research Institute | Composición de ADN para inducir una respuesta inmunitaria contra macrófagos asociados a tumor |
WO2009046388A1 (en) * | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
WO2009120811A1 (en) | 2008-03-25 | 2009-10-01 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
WO2010051210A1 (en) | 2008-10-31 | 2010-05-06 | Boehringer Ingelheim Vetmedica, Inc. | Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition |
RU2570732C9 (ru) * | 2009-05-14 | 2016-09-10 | Байер Интеллектуэль Проперти Гмбх | Усиленный иммунный ответ у видов птиц |
MX345854B (es) | 2010-12-22 | 2017-02-17 | Bayer Ip Gmbh | Respuesta inmune potenciada en la especie bovina. |
CL2011000065A1 (es) | 2011-01-11 | 2011-04-15 | Univ Concepcion | Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos. |
JP6772065B2 (ja) * | 2014-02-28 | 2020-10-21 | バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh | 免疫賦活プラスミド |
-
2015
- 2015-02-27 JP JP2016554261A patent/JP6772065B2/ja active Active
- 2015-02-27 PE PE2016001534A patent/PE20170404A1/es not_active Application Discontinuation
- 2015-02-27 RU RU2016138321A patent/RU2740492C2/ru active
- 2015-02-27 UA UAA201609729A patent/UA118374C2/uk unknown
- 2015-02-27 KR KR1020167026797A patent/KR20160122849A/ko unknown
- 2015-02-27 CA CA2940794A patent/CA2940794C/en active Active
- 2015-02-27 MX MX2016010993A patent/MX2016010993A/es unknown
- 2015-02-27 EP EP15707606.8A patent/EP3110940A1/en not_active Ceased
- 2015-02-27 US US14/633,920 patent/US10155950B2/en active Active
- 2015-02-27 CR CR20160393A patent/CR20160393A/es unknown
- 2015-02-27 AU AU2015222102A patent/AU2015222102B2/en active Active
- 2015-02-27 CN CN201580010413.0A patent/CN106029867B/zh active Active
- 2015-02-27 BR BR112016019837A patent/BR112016019837A2/pt not_active Application Discontinuation
- 2015-02-27 WO PCT/EP2015/054131 patent/WO2015128461A1/en active Application Filing
-
2016
- 2016-08-02 IL IL247065A patent/IL247065A0/en unknown
- 2016-08-08 ZA ZA2016/05495A patent/ZA201605495B/en unknown
- 2016-08-24 CL CL2016002146A patent/CL2016002146A1/es unknown
- 2016-08-26 SV SV2016005263A patent/SV2016005263A/es unknown
- 2016-08-26 PH PH12016501705A patent/PH12016501705A1/en unknown
- 2016-08-26 DO DO2016000223A patent/DOP2016000223A/es unknown
-
2018
- 2018-04-25 US US15/962,414 patent/US10851379B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2740492C2 (ru) | 2021-01-14 |
US10851379B2 (en) | 2020-12-01 |
WO2015128461A1 (en) | 2015-09-03 |
CA2940794A1 (en) | 2015-09-03 |
ZA201605495B (en) | 2022-08-31 |
CN106029867A (zh) | 2016-10-12 |
JP6772065B2 (ja) | 2020-10-21 |
AU2015222102A1 (en) | 2016-08-18 |
RU2016138321A3 (es) | 2018-11-12 |
SV2016005263A (es) | 2018-01-16 |
CN106029867B (zh) | 2020-02-14 |
AU2015222102B2 (en) | 2021-08-19 |
CR20160393A (es) | 2017-12-14 |
KR20160122849A (ko) | 2016-10-24 |
PE20170404A1 (es) | 2017-05-14 |
BR112016019837A2 (pt) | 2017-10-17 |
CA2940794C (en) | 2022-05-31 |
EP3110940A1 (en) | 2017-01-04 |
US20180312842A1 (en) | 2018-11-01 |
DOP2016000223A (es) | 2016-09-30 |
US20150267201A1 (en) | 2015-09-24 |
US10155950B2 (en) | 2018-12-18 |
PH12016501705A1 (en) | 2016-10-03 |
RU2016138321A (ru) | 2018-03-30 |
JP2017512202A (ja) | 2017-05-18 |
UA118374C2 (uk) | 2019-01-10 |
CL2016002146A1 (es) | 2017-08-04 |
IL247065A0 (en) | 2016-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501705A1 (en) | Immunostimulatory plasmids | |
MX2021000285A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12018502118A1 (en) | Chimeric receptors to flt3 and methods of use thereof | |
IL288784A (en) | Antibodies against garp, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof | |
MX2021014956A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
MX2017001406A (es) | Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva. | |
MX2021009001A (es) | Composiciones microbianas para alimentacion directa y sus metodos de uso. | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2016003944A (es) | Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos. | |
IL247469A0 (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
PH12014502855A1 (en) | Attenuated streptococcus suis vaccines and methods of making and use thereof | |
MX2017002085A (es) | Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. | |
MX2017009720A (es) | Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas. | |
MX2015014190A (es) | Construccion de adn inmunomoduladora no codificante cerrada covalentemente. | |
NZ724908A (en) | Immunological compositions containing attenuated histophilus somni | |
MX2017006625A (es) | Mutantes de neumolisina y metodos de uso de los mismos. | |
MX2017009682A (es) | Composiciones de caldo y su uso como prebioticos. | |
MX2017016401A (es) | Composiciones inmunogenas. | |
MX2016017084A (es) | Composiciones y metodos para mejorar la inmunidad. | |
PH12019501173A1 (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
HK1255944A1 (zh) | 抗病原體的柑橘類組合物、有機體、系統和方法 | |
NZ721832A (en) | Solid forms of tenofovir | |
MA39900A (fr) | Vaccins à base d'acide nucléique |